We continue to evolve driven by this fundamental objective as we grow our marketed products and progress our pipeline. Our focus to optimize global brands and key markets accelerated growth of several key products. We are developing new medicines in the following core therapeutic areas: oncology, virology, immuno-oncology, specialty cardiovascular disease, fibrosis, and genetically defined diseases. We continue to invest significantly in our deep pipeline of innovative medicines covering a broad array of cancers and have entered into several collaboration agreements to research and develop opdivo and other approved or investigational oncology agents in combination regimens. Our R&D programs are managed on a portfolio basis from early discovery through late-stage development. We continually evaluate our portfolio to ensure that there is an appropriate balance of early-stage and late-stage programs to support future growth. Our late-stage development programs could potentially have an impact on our revenue and earnings within the next few years. We are evolving our commercial model and growing our marketed product portfolio in a manner consistent with our overall strategy. We continue to implement our biopharma strategy by driving the growth of key brands, executing new product launches, investing in our pipeline, focusing on prioritized markets, increasing investments in our biologics manufacturing capabilities, maintaining a culture of continuous improvement, and pursuing disciplined capital allocation, including through business development. We recognize the importance of operational flexibility and adaptability in response to environmental perturbations and external pressures. Our strategic initiatives include enhancing our organizational capabilities and ensuring effective resource allocation to navigate complex situations and disruptions in the market. We are committed to maintaining a culture of innovation and resilience, which enables us to confront challenges and leverage opportunities for growth. The evolution of our business is also characterized by our ability to absorb strain and preserve or improve functioning despite the presence of adversity. We have established mechanisms for risk assessment and mitigation, ensuring that we can respond effectively to unexpected situations and maintain operational continuity. Our financial position reflects a proactive approach to managing resources and capital, enabling us to sustain performance under pressure. We continue to monitor the economic conditions in various markets, which may impact our strategic response and operational management. Our commitment to collaboration networks and inter-organizational collaboration enhances our resilience strategies, allowing us to adapt to changing market dynamics. We remain focused on our major objectives, ensuring that we deploy resources effectively to achieve organizational success. The strategic foresight embedded in our planning processes positions us to navigate future uncertainties and capitalize on emerging opportunities. Our organizational practices emphasize the importance of learning and knowledge management, fostering an environment where innovation can flourish. We recognize the multifaceted nature of resilience, which involves not only maintaining performance but also reconfiguring our approach to meet evolving customer needs and market demands.